DARA BioSciences, Inc
(NASDAQ:
DARA)
Biotechnology - Healthcare
|
| Last Price |
Today's Change |
Day's Range |
Volume |
| $0.85 |
-0.02
(-2.35 %)
|
$0.83 - $0.86 |
22.33K
|
|
| |
| Previous Close |
$0.87 |
|
|
Average Volume |
88.96K
|
| Open |
$0.83 |
|
|
EPS |
-1.19 |
| Market Cap |
0.01B
|
|
|
PE |
0.00 |
| Shares Outstanding |
7.70M
|
|
|
Relative Strength Index (14) |
34.69 |
| Float Shares |
6.54M
|
|
|
Moving Average (20) |
-6.01 % |
| Institutional Ownership |
0.77 % |
|
|
Moving Average (50) |
-26.82 % |
| Insider Ownership |
3.01 % |
|
|
Moving Average (200) |
-44.59 % |
| Beta |
1.74 |
|
|
Analyst Recommendation |
Buy |
| Dividend Yield |
0.0 % |
|
|
Earnings Date |
Mar 19, 2012 |
|
| |
Performance Metrics |
| Week |
Month |
Quarter |
Half Year |
Year |
|
-8.42
%
|
-3.33
%
|
-66.54
%
|
-44.94
%
|
-66.79
%
|
|
| |
| |
Company Information |
DARA BioSciences, Inc., a development-stage pharmaceutical company, acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. The company has two drug candidates in development with cleared investigational new drug applications from the U.S. Food and Drug Administration. Its drug development programs include KRN5500, which completed a Phase IIa clinical trial for the treatment of neuropathic pain in cancer patients; and DB959 for the treatment of metabolic diseases, including type 2 diabetes. The company is headquartered in Raleigh, North Carolina.
|
|
| Last Price |
Today's Change |
Day's Range |
Volume |
| $0.85 |
-0.02
(-2.35 %)
|
$0.83 - $0.86 |
22.33K
|
|
| |
| |
|
|
|
| Last Price |
Today's Change |
Day's Range |
Volume |
| $0.85 |
-0.02
(-2.35 %)
|
$0.83 - $0.86 |
22.33K
|
|
| |
| |
|
|
